Geographical and socioeconomic inequalities in female breast cancer incidence and mortality in Iran: A Bayesian spatial analysis of registry data.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
11
2020
accepted:
03
03
2021
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
13
10
2021
Statut:
epublish
Résumé
In Iran, trends in breast cancer incidence and mortality have generally been monitored at national level. The purpose of this study is to examine province-level disparities in age-standardised breast cancer incidence versus mortality from 2000 to 2010 and their association with socioeconomic status. In this study, data from Iran's national cancer and death registry systems, and covariates from census and household expenditure surveys were used. We estimated the age-standardised incidence and mortality rates in women aged more than 30 years for all 31 provinces in the consecutive time intervals 2000-2003, 2004-2007 and 2008-2010 using a Bayesian spatial model. Mean age-standardised breast cancer incidence across provinces increased over time from 15.0 per 100,000 people (95% credible interval 12.0,18.3) in 2000-2003 to 39.6 (34.5,45.1) in 2008-2010. The mean breast cancer mortality rate declined from 10.9 (8.3,13.8) to 9.9 (7.5,12.5) deaths per 100,000 people in the same period. When grouped by wealth index quintiles, provinces in the highest quintile had higher levels of incidence and mortality. In the wealthiest quintile, reductions in mortality over time were larger than those observed among provinces in the poorest quintile. Relative breast cancer mortality decreased by 16.7% in the highest quintile compared to 10.8% in the lowest quintile. Breast cancer incidence has increased over time, with lower incidence in the poorest provinces likely driven by underdiagnoses or late-stage diagnosis. Although the reported mortality rate is still higher in wealthier provinces, the larger decline over time in these provinces indicates a possible future reversal, with the most deprived provinces having higher mortality rates. Ongoing analysis of incidence and mortality at sub-national level is crucial in addressing inequalities in healthcare systems and public health both in Iran and elsewhere.
Sections du résumé
BACKGROUND
In Iran, trends in breast cancer incidence and mortality have generally been monitored at national level. The purpose of this study is to examine province-level disparities in age-standardised breast cancer incidence versus mortality from 2000 to 2010 and their association with socioeconomic status.
METHODS
In this study, data from Iran's national cancer and death registry systems, and covariates from census and household expenditure surveys were used. We estimated the age-standardised incidence and mortality rates in women aged more than 30 years for all 31 provinces in the consecutive time intervals 2000-2003, 2004-2007 and 2008-2010 using a Bayesian spatial model.
RESULTS
Mean age-standardised breast cancer incidence across provinces increased over time from 15.0 per 100,000 people (95% credible interval 12.0,18.3) in 2000-2003 to 39.6 (34.5,45.1) in 2008-2010. The mean breast cancer mortality rate declined from 10.9 (8.3,13.8) to 9.9 (7.5,12.5) deaths per 100,000 people in the same period. When grouped by wealth index quintiles, provinces in the highest quintile had higher levels of incidence and mortality. In the wealthiest quintile, reductions in mortality over time were larger than those observed among provinces in the poorest quintile. Relative breast cancer mortality decreased by 16.7% in the highest quintile compared to 10.8% in the lowest quintile.
CONCLUSIONS
Breast cancer incidence has increased over time, with lower incidence in the poorest provinces likely driven by underdiagnoses or late-stage diagnosis. Although the reported mortality rate is still higher in wealthier provinces, the larger decline over time in these provinces indicates a possible future reversal, with the most deprived provinces having higher mortality rates. Ongoing analysis of incidence and mortality at sub-national level is crucial in addressing inequalities in healthcare systems and public health both in Iran and elsewhere.
Identifiants
pubmed: 33730079
doi: 10.1371/journal.pone.0248723
pii: PONE-D-20-37155
pmc: PMC7968648
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248723Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Glob Health. 2015 Apr;3(4):e229-39
pubmed: 25794676
Asian Pac J Cancer Prev. 2015;16(18):8439-43
pubmed: 26745098
Arch Iran Med. 2008 Sep;11(5):577-80
pubmed: 18759534
Br J Cancer. 2007 Mar 12;96(5):836-40
pubmed: 17311024
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2015-2020
pubmed: 31350959
Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):327-30
pubmed: 18712985
Lancet. 2011 Oct 22;378(9801):1461-84
pubmed: 21924486
Asian Pac J Cancer Prev. 2014;15(4):1557-61
pubmed: 24641367
Health Care Women Int. 2010 Jun;31(6):499-514
pubmed: 20461601
Emerg (Tehran). 2015 Winter;3(1):16-21
pubmed: 26512364
Int J Breast Cancer. 2017;2017:2481021
pubmed: 29201466
J Med Life. 2019 Apr-Jun;12(2):140-149
pubmed: 31406515
Asian Pac J Cancer Prev. 2015;16(14):6081-7
pubmed: 26320499
Arch Iran Med. 2014 Mar;17(3):176-81
pubmed: 24621360
Asian Pac J Cancer Prev. 2010;11(4):1155-7
pubmed: 21133641
Arch Intern Med. 2002 Sep 23;162(17):1985-93
pubmed: 12230422
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
JAMA Oncol. 2017 Sep 01;3(9):1228-1236
pubmed: 28152151
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Asian Pac J Cancer Prev. 2004 Jan-Mar;5(1):24-7
pubmed: 15075000
Breast Cancer Res Treat. 2013 Sep;141(2):225-9
pubmed: 24036692
Arch Iran Med. 2017 Jan;20(1):2-11
pubmed: 28112524
Breast Cancer Res. 2004;6(6):229-39
pubmed: 15535852
J Natl Cancer Inst. 1965 May;34:553-69
pubmed: 14313816
J Glob Oncol. 2018 Jul;4:1-16
pubmed: 30085889
Front Oncol. 2020 Jan 14;9:1428
pubmed: 31993366
J Clin Oncol. 2019 Jun 20;37(18):1566-1575
pubmed: 31046551
Arch Iran Med. 2014 Jan;17(1):7-15
pubmed: 24444059
Geospat Health. 2018 May 08;13(1):645
pubmed: 29772889
Open Access Maced J Med Sci. 2019 Feb 15;7(4):637-642
pubmed: 30894928
Arch Iran Med. 2014 Mar;17(3):193-7
pubmed: 24621363
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Asian Pac J Cancer Prev. 2012;13(1):367-70
pubmed: 22502702
J Oncol. 2010;2010:490631
pubmed: 21209708
ESMO Open. 2018 Feb 2;3(2):e000285
pubmed: 29464109
Eur J Cancer Prev. 2008 Jun;17(3):218-24
pubmed: 18414192
Biometrika. 1950 Jun;37(1-2):178-81
pubmed: 15420264
Int J Epidemiol. 2012 Dec;41(6):1737-49; discussion 1750-2
pubmed: 23129720
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Rev Med Moyen Orient. 1962 Mar-Apr;19:302-8
pubmed: 13903402
Epidemiology. 2004 May;15(3):300-7
pubmed: 15097010
J Epidemiol Community Health. 1994 Feb;48(1):65-73
pubmed: 8138773
Iran J Public Health. 2015 Mar;44(3):430-1
pubmed: 25905094
J Epidemiol Community Health. 2006 Mar;60(3):208-12
pubmed: 16476749
Asian Pac J Cancer Prev. 2012;13(9):4517-20
pubmed: 23167371
Ann Oncol. 2009 Mar;20(3):556-63
pubmed: 19073863